Latest news with #BostonScientific
Yahoo
8 hours ago
- Business
- Yahoo
Baxter (BAX) Reports Earnings Tomorrow: What To Expect
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here's what to expect. Baxter beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.63 billion, up 5.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' constant currency revenue estimates and an impressive beat of analysts' EPS estimates. Is Baxter a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Baxter's revenue to grow 4.7% year on year to $2.82 billion, in line with the 4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.61 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street's revenue estimates six times over the last two years. Looking at Baxter's peers in the medical devices & supplies - diversified segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Neogen reported a revenue decline of 4.8%, topping estimates by 1.3%. Boston Scientific traded up 2.9% following the results. Read our full analysis of Boston Scientific's results here and Neogen's results here. Investors in the medical devices & supplies - diversified segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Baxter is down 5.2% during the same time and is heading into earnings with an average analyst price target of $37.09 (compared to the current share price of $28.70). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Amneal Pharmaceuticals is one of 984 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 4.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that AMRX has returned about 1.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This means that Amneal Pharmaceuticals is performing better than its sector in terms of year-to-date returns. Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX). The stock has returned 18.8% year-to-date. In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy). To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 6.8% so far this year, so AMRX is slightly underperforming its industry in this area. In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #173. Since the beginning of the year, the industry has moved +6.7%. Amneal Pharmaceuticals and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Boston Scientific Corporation (BSX) Is One Of The Most Reliable Companies, Says Jim Cramer
We recently published . Boston Scientific Corporation (NYSE:BSX) is one of the stocks Jim Cramer recently discussed. Boston Scientific Corporation (NYSE:BSX) is one of the biggest medical device companies in the world. Its shares have gained 18.9% year to date, with July proving to be a good month. Boston Scientific Corporation (NYSE:BSX)'s shares rose by 4.5% after its latest quarterly results, which saw the firm's cardiovascular business grow sales by 23% organically to smash analyst estimates of 5% out of the park. Cramer commented on the results: 'The most reliable medical equipment company. . .Boston Scientific. Another great quarter. Mike Mahoney quietly puts up a fantastic number, fantastic. Big revenue beat. Some people are just so unheralded and this again is the broadening out. I know that we can worry about 2008. I know we can worry about 2021. But there are sectors of the market where the companies are just crushing it. Like them.' A medical technician holding the instruments in her hands Previously, Cramer commented on Boston Scientific Corporation (NYSE:BSX)'s business: 'Now it was a big cluster with gains in the mid-fifties… Finally, there's Boston Scientific, which makes minimally invasive medical devices. We've had them on… Some would say it just builds a better mousetrap, crude and somewhat denigrating but true, a superior company.' While we acknowledge the potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
